Adam Mirando’s research focuses on the study and development of a series of peptides derived from natural sequences within the human proteome to develop novel therapeutic agents for clinical use. Specifically, these efforts focus on the effects of peptides on vessel stability and inflammation as well as how these vascular effects impact immune processes with an emphasis on oncological and ophthalmological systems. Techniques include a variety of biophysical and biochemical assays, cellular work, and animal models to assess peptide activity and peptide sequence, and structural software to identify potential mutation sites that could be used to alter the properties of the peptides for increased solubility, stability, and activity.